Elsevier

Clinics in Chest Medicine

Volume 36, Issue 4, December 2015, Pages 669-683
Clinics in Chest Medicine

Ocular Sarcoidosis

https://doi.org/10.1016/j.ccm.2015.08.009Get rights and content

Section snippets

Key points

  • Ocular sarcoidosis can involve any part of the eye and its adnexal tissues.

  • The most common ocular manifestations are uveitis, dry eye, and conjunctival nodules.

  • Ocular involvement is the presenting symptom in approximately 20% to 30% of patients with sarcoidosis.

  • Multidisciplinary approaches are required to achieve the best treatment outcomes for both ocular and systemic manifestations.

  • With appropriate treatment, visual prognosis is generally good.

Sarcoidosis can involve almost any structure

Epidemiology

Ocular involvement of sarcoidosis has been known since the early 1900s and has become more recognized since the mid-1900s.1 Variability in the diagnostic criteria has made epidemiologic studies of ocular sarcoidosis challenging.

The prevalence of ocular involvement in different series ranges widely from 13% (Turkish study) to 79% (Japanese study) in patients with systemic sarcoidosis.2, 3, 4 Ocular involvement is the presenting symptom in approximately 20% to 30%.5, 6 Uveitis was reported in 30%

Clinical manifestations of ocular sarcoidosis

Ocular disease may be the initial manifestation in patients with sarcoidosis and may cause severe visual impairment. The involvement may be characterized by granulomatous inflammation, which can affect any part of the eye and its adnexa. Examples of the clinical presentations of ocular sarcoidosis are listed in Table 1. The most common ocular manifestations are uveitis, dry eye, and conjunctival nodules.

Diagnosis of ocular sarcoidosis

Sarcoidosis is one of several conditions that may simultaneously involve multiple ocular tissues with various presentations. For example, patients may present with acute anterior uveitis with lacrimal gland enlargement, bilateral multifocal choroiditis with conjunctival nodules, or peripheral ulcerative keratitis with orbital inflammation. Sarcoidosis should be particularly high on differential diagnoses in those with involvement of multiple ocular tissues.

The gold standard for the diagnosis of

Treatment of ocular sarcoidosis

The primary aims for the management of ocular sarcoidosis are to restore vision and to prevent complications from related inflammation. Corticosteroid therapy, including topical, regional, and systemic routes, is the mainstay of treatment. Other immunomodulators may be required in some patients who are dependent, unresponsive, or intolerant to corticosteroid treatment.

Prognosis of ocular sarcoidosis

Visual prognosis of ocular sarcoidosis may vary depending on the severity and chronicity of eye inflammation, a delay in presentation to a specialist, and ocular complications secondary to uveitis.9 A long-term prognostic study of sarcoid uveitis showed that most (54%) patients retained vision of better than 20/40 in both eyes and that only 4.6% had lost vision less than 20/120 in both eyes, at 10 years after the onset of uveitis in a setting of an ophthalmic referral center.120 The main causes

First page preview

First page preview
Click to open first page preview

References (121)

  • W.P. Riono et al.

    Scleritis: a clinicopathologic study of 55 cases

    Ophthalmology

    (1999)
  • H. Demirci et al.

    Orbital and adnexal involvement in sarcoidosis: analysis of clinical features and systemic disease in 30 cases

    Am J Ophthalmol

    (2011)
  • K.L. Chapman et al.

    Lacrimal bypass surgery in patients with sarcoidosis

    Am J Ophthalmol

    (1999)
  • D.J. Kay et al.

    Isolated sarcoidosis of the lacrimal sac without systemic manifestations

    Am J Otolaryngol

    (2002)
  • D.A. Jabs et al.

    Ocular involvement in chronic sarcoidosis

    Am J Ophthalmol

    (1986)
  • C.W. Nichols et al.

    Conjunctival biopsy as an aid in the evaluation of the patient with suspected sarcoidosis

    Ophthalmology

    (1980)
  • Z.A. Karcioglu et al.

    Conjunctival biopsy in sarcoidosis

    Am J Ophthalmol

    (1985)
  • J.T. Rosenbaum et al.

    Hypothesis: sarcoidosis is a STAT1-mediated disease

    Clin Immunol

    (2009)
  • G.J. Jaffe et al.

    Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study

    Ophthalmology

    (2006)
  • S. Dev et al.

    Methotrexate treatment for sarcoid-associated panuveitis

    Ophthalmology

    (1999)
  • R.C. Walton et al.

    Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents

    Ophthalmology

    (1998)
  • D.A. Jabs et al.

    Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel

    Am J Ophthalmol

    (2000)
  • S. Pasadhika et al.

    Azathioprine for ocular inflammatory diseases

    Am J Ophthalmol

    (2009)
  • R.O. Kacmaz et al.

    Cyclosporine for ocular inflammatory diseases

    Ophthalmology

    (2010)
  • J.D. Doty et al.

    Treatment of sarcoidosis with infliximab

    Chest

    (2005)
  • M. Cordero-Coma et al.

    Golimumab for uveitis

    Ophthalmology

    (2011)
  • R.P. Crick et al.

    The eyes in sarcoidosis

    Br J Ophthalmol

    (1961)
  • A. Rothova

    Ocular involvement in sarcoidosis

    Br J Ophthalmol

    (2000)
  • L.S. Atmaca et al.

    Ocular involvement in sarcoidosis

    Ocul Immunol Inflamm

    (2009)
  • K. Ohara et al.

    Intraocular manifestations of systemic sarcoidosis

    Jpn J Ophthalmol

    (1992)
  • A. Heiligenhaus et al.

    The eye as a common site for the early clinical manifestation of sarcoidosis

    Ophthalmic Res

    (2011)
  • A. Rothova et al.

    Risk factors for ocular sarcoidosis

    Doc Ophthalmol

    (1989)
  • C.D. Rose et al.

    Pediatric granulomatous arthritis: an international registry

    Arthritis Rheum

    (2006)
  • M. Evans et al.

    Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis

    Ophthalmology

    (2007)
  • A.D. Birnbaum et al.

    Clinical features and diagnostic evaluation of biopsy-proven ocular sarcoidosis

    Arch Ophthalmol

    (2011)
  • J.A. Smith et al.

    Epidemiology and course of disease in childhood uveitis

    Ophthalmology

    (2009)
  • A. Rodriguez et al.

    Referral patterns of uveitis in a tertiary eye care center

    Arch Ophthalmol

    (1996)
  • P.T. Merrill et al.

    Uveitis in the southeastern United States

    Curr Eye Res

    (1997)
  • G. Sungur et al.

    Pattern of ocular findings in patients with biopsy-proven sarcoidosis in Turkey

    Ocul Immunol Inflamm

    (2013)
  • S. Abad et al.

    Association of peripheral multifocal choroiditis with sarcoidosis: a study of thirty-seven patients

    Arthritis Rheum

    (2004)
  • D.A. Jabs et al.

    Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

    Am J Ophthalmol

    (2005)
  • D.J. Spalton et al.

    Fundus changes in histologically confirmed sarcoidosis

    Br J Ophthalmol

    (1981)
  • C.E. Letocha et al.

    Retinal changes in sarcoidosis

    Can J Ophthalmol

    (1975)
  • H. Gould et al.

    Sarcoid of the fundus

    Arch Ophthalmol

    (1961)
  • H.A. Hoogstede et al.

    A case of macular subretinal neovascularisation in chronic uveitis probably caused by sarcoidosis

    Br J Ophthalmol

    (1982)
  • R.N. Khurana et al.

    Sarcoid choroiditis simulating birdshot chorioretinopathy

    Retin Cases Brief Rep

    (2008)
  • P. Delaney

    Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases

    Ann Intern Med

    (1977)
  • Y.L. Phillips et al.

    Neuro-ophthalmic sarcoidosis

    Curr Opin Ophthalmol

    (2010)
  • J.D. Gass et al.

    Sarcoidosis with optic nerve and retinal involvement

    Arch Ophthalmol

    (1976)
  • J.P. Zajicek et al.

    Central nervous system sarcoidosis–diagnosis and management

    QJM

    (1999)
  • Cited by (161)

    • Ocular Sarcoidosis

      2024, Clinics in Chest Medicine
    • Sarcoidosis

      2023, Immunology and Allergy Clinics of North America
    View all citing articles on Scopus

    Dr S. Pasadhika has no conflict of interests to disclose.

    Dr J.T. Rosenbaum is a consultant for Abbvie, UCB, Genentech, Medimmune, Xoma, Portage, Auventx, Santen, Sanofi, and Regeneron.

    View full text